SalioGen Therapeutics
SalioGen Therapeutics was a preclinical genetic medicine company developing a proprietary platform for inherited retinal disorders. The venture-backed biotech raised approximately $135 million before ceasing operations by 2025, without advancing to clinical-stage development.
- Company typePrivate
- Founded2020
- HeadquartersBurlington, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
SalioGen Therapeutics firmographics
Firmographics- Name
- SalioGen Therapeutics
- Legal name
- SalioGen Therapeutics
- Website
- https://saliogen.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- SalioGen Therapeutics was a preclinical genetic medicine company developing a proprietary platform for inherited retinal disorders. The venture-backed biotech raised approximately $135 million before ceasing operations by 2025, without advancing to clinical-stage development.
- Ownership category
- akta.pro rank
SalioGen Therapeutics industry classification
Industry- Product category
- Gene Therapy / Genetic Medicine
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Ophthalmology Gene Therapies (HLAAACAG)
- akta.pro secondary industries
- Rare Ophthalmology Disorder Therapies (HLAIAIAK), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where SalioGen Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SalioGen Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Pre-revenue: The company was in preclinical research stage and is no longer operating. No commercial revenue was generated.
SalioGen Therapeutics product offering
Product offeringCore offering
SalioGen Therapeutics was a preclinical-stage genetic medicine company developing a proprietary gene coding platform intended to produce potentially curative therapies for patients with inherited disorders, with an initial focus on inherited retinal dystrophies. The company ceased operations in 2025 and had not advanced any therapeutic candidates to clinical or commercial stage during its operating history.
Differentiator
Problem solved
Functional benefit
Products and services
- Genetic Medicines Platform
Companies that use SalioGen Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
SalioGen Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
SalioGen Therapeutics partnerships and signals
Strategic signalScale indicators2 records
SalioGen Therapeutics competitors and assessment
Company assessmentDirect peers
- MeiraGTx Holdings: Clinical-stage gene therapy company with multiple inherited retinal disorder programs (e.g., AAV-RPGR for X-linked retinitis pigmentosa) and in-house manufacturing — a direct comparable in both indication and vertical-integration strategy.
- Adverum Biotechnologies: Clinical-stage gene therapy developer with lead programs in wet AMD and diabetic retinopathy, competing for the same retinal disorder patient populations and investor mindshare as SalioGen.
- Editas Medicine: Gene-editing company with a clinical-stage program (EDIT-101/reniogene zamparparvovec) in Leber congenital amaurosis 10, directly competing in inherited retinal disorder gene therapy.
- REGENXBIO: AAV gene therapy platform company with clinical-stage retinal programs (e.g., RGX-314) partnered with AbbVie, competing both as a platform licensor and as an IRD therapeutics developer.
- GenSight Biologics: Gene therapy company developing therapies for inherited retinal diseases and optic neuropathies (e.g., Lumevoq for LHON), making it a direct peer in the IRD gene therapy category.
Broad incumbents
- Spark Therapeutics (Roche): Pioneer in IRD gene therapy (approved Luxturna/voretigene neparvovec for RPE65-mediated IRDs), now a Roche subsidiary; a broad incumbent that defines the regulatory and commercial benchmark for any IRD gene therapy entrant.
Emerging players
- 4D Molecular Therapeutics: Clinical-stage company engineering novel AAV capsids for targeted gene therapy delivery, with retinal disease programs, making it a platform-level peer in next-generation gene therapy delivery.
- Nanoscope Therapeutics: Clinical-stage optogenetics and gene therapy company focused on retinal degenerative diseases (e.g., retinitis pigmentosa and Stargardt disease), addressing the same patient populations as SalioGen via a different modality.
- ProQR Therapeutics: RNA-editing company developing Axiomer-based therapies for inherited retinal diseases (e.g., Leber congenital amaurosis and Usher syndrome), an adjacent but modality-adjacent peer in the same indication space.
Others
- Krystal Biotech: Commercial-stage genetic medicines company with a non-viral, redosable platform and approved product (Vyjuvek); comparable as a small genetic-medicine platform that successfully traversed from preclinical to commercial stage, providing a strategic reference point for what SalioGen aspired to build.
Market position
Customer concentration
SalioGen Therapeutics social profiles
Digital presenceSalioGen Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
SalioGen Therapeutics leadership team
Management profileNumber of profiles
SalioGen Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SalioGen Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SalioGen Therapeutics
What does SalioGen Therapeutics do?
SalioGen Therapeutics was a preclinical-stage genetic medicine company developing a proprietary gene coding platform intended to produce potentially curative therapies for patients with inherited disorders, with an initial focus on inherited retinal dystrophies. The company ceased operations in 2025 and had not advanced any therapeutic candidates to clinical or commercial stage during its operating history.
Is SalioGen Therapeutics a public or private company?
SalioGen Therapeutics is a private company. It is classified as venture growth investor backed and is currently closed.
When was SalioGen Therapeutics founded?
SalioGen Therapeutics was founded in 2020. It employs 11 to 50 people.
Where is SalioGen Therapeutics based?
SalioGen Therapeutics is headquartered in Burlington, United States, in the North America region.
How does SalioGen Therapeutics make money?
One revenue line is on record: pre-revenue.
Who are SalioGen Therapeutics's main competitors?
Direct peers on record are MeiraGTx Holdings, Adverum Biotechnologies, Editas Medicine, REGENXBIO and GenSight Biologics. Spark Therapeutics (Roche) is listed as a broad incumbent. Emerging players are 4D Molecular Therapeutics, Nanoscope Therapeutics and ProQR Therapeutics. Krystal Biotech is listed as an others.
Does SalioGen Therapeutics have an API?
No public API is recorded for SalioGen Therapeutics.
What industry is SalioGen Therapeutics in?
SalioGen Therapeutics's product category is Gene Therapy / Genetic Medicine. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 541714.